Biotherapeutics company focused on discovering and developing antibodies and antibody-drug conjugates (ADCs) for cancer treatment
Biotherapeutics company focused on discovering and developing antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Its integrated platform supports target and functional antibody discovery and the generation of site-specific, homogeneous ADC candidates. Pipeline programs included candidates for hematologic and solid tumors and immunotherapy.